The enhancement in CD8+ TIL activation with CD28 costimulation was blocked following the addition of the glycolytic inhibitor 2-DG, indicating that the breakdown of glucose was necessary for downstream metabolic pathways serving the energetic needs of activated CD8+ RCC TILs. The gene discussed is CD28; the disease is renal cell carcinoma.